Almost there, just wait and see!
be patient guys!
Advaxis is in a much better position, remember we are a phase 3 company
one of them with solid cash, data , technology! combo data with merck, medImmune at 2nd half year could bring us to the top! IMO
Still have my dream! overall biotech and health care are sucks this year, but Advaxis is my number one in my portforlio, because of they are at the edge of commercialize of their products, that's very important!
it is not the end of world for biotech, i see more deals this year
Gilead looking for deals, Merck looking for deals, Pfizer looking for deal, all big pharmas is looking for deals for the next generation cancer Immu therapy. Advaxis is well prepared for the best position. IMO
Sentiment: Strong Buy
I don't see it on the website.
well, let's see how long we have to wait
I think Huawei and samsung or Xiaomi will get much more market shares in the world!
I trust Dan, I believe LM science, no regret put all money in Advaxis, just wait and see!
Paris (AFP) - French pharmaceutical giant Sanofi said Thursday it had made a bid to acquire Medivation in a deal valuing the US cancer drug firm at around $9.3 billion (8.2 billion euros).
Under terms of the offer, Sanofi would pay $52.50 per share in cash for the San Francisco-based firm, which specialises in cancer treatments.
If the bid is accepted, it would be Sanofi's biggest acquisition since it bought the US biotech group Genzyme in 2011 for more than $20 billion.
"Thanks to Medivation's excellent prostate cancer treatments, we believe that a merger with Medivation would benefit patients and, at the same time, create value for shareholders in both companies," said Sanofi's chief executive Olivier Brandicourt in a statement.
Sanofi is the 11th largest pharmaceutical company in the world by stock market valuation and the second biggest firm in France after oil giant Total with a market capitalisation which stood at around 100 billion euros on Thursday.
This is what I'm talking about! Time will come for Advaxis!
Stemcentrx, a startup with backing from Silicon Valley investors including Artis Ventures and Founders Fund, was just acquired by AbbVie for $5.8 billion in cash and stock.
to this. with combo data with medImmune, combo data with merck on the way 2H 2016, we could break triple digit by November, I think both data could add $3-4$ billion MC, IMHO.
Sentiment: Strong Buy
last march 2015 he said don't buy, stock went up to $30.00
That's the reason we are here!